April 26, 2010 (Barcelona, Spain) — The gonadotropin-releasing hormone (GnRH) agonist histrelin acetate (VantasR), administered as a 50 mg subdermal implant once yearly, retained its effectiveness ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

While islet cell transplants allow some diabetics to forgo daily insulin injections, those people have to take immunosuppressive drugs in order to keep the cells from being rejected. A new implant, ...

Company to Proceed with Phase 2 Development Program for Islatravir Subdermal Implant “We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen ...

Phase 1 Data Presented Today at IAS 2019 KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today results from a Phase 1 study ...

On Tuesday, Vivani Medical Inc (NASDAQ:VANI) announced the publication of positive proof-of-concept weight loss data with OKV-119 to treat feline obesity and diabetes in the peer-reviewed BMC ...

Subdermal delivery of antiretrovirals shows promise in early trials Clinicians acknowledge that one of the main drawbacks in current HIV treatments is the problem of adherence. Findings published this ...

Little-known emerging biopharmaceutical company Vivani Medical (NASDAQ:VANI) saw its market value increase dramatically on Wednesday. Catapulting sentiment was the company’s weight-loss solution, ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 1 study evaluating the safety, tolerability and ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today results from a Phase 1 study evaluating the pharmacokinetics and safety of a ...